The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
Year: 2020
Type: article
Abstract: The outbreak of SARS-CoV-2, the cause of COVID-19, is ongoing. New and effective antiviral agents that combat the disease are needed urgently. Here, we found that an inhaled corticosteroid, ciclesonide, suppresses the replication of coronaviruses, including betacoronaviruses (murine hepatitis virus type 2 [MHV-2], MERS-CoV, SARS-CoV, and SARS-CoV-2) and an alphacoronavirus (human coronavirus 229E [HCoV-229E]), in cultured cells. Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. Thus, ciclesonide is expected to be a broad-spectrum antiviral drug that is effective against many members of the coronavirus family. It could be prescribed for the treatment of MERS and COVID-19.
Source: Journal of Virology
DOI: 10.1128/jvi.01648-20
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1390002646, Activation mechanism of coronavirus membrane fusion protein, G3020948730, G3519006882, G4054653383, モノアミンニューロンの研究における螢光組織化学法の応用, Elucidation of the mechanism of inhibition of coronavirus DMVs formation by approved drugs., G5929952504, Innate immune responses induced by two coronavirus cell entry pathways
OpenAlex ID: W3092775354
